

Table S1 Univariate and multivariate analyses of OS in 50 cases of non-MALT lymphoma

Factors	No. (%)	Univariate analysis			Multivariate analysis		
		HR	95% CI	P-value	HR	95% CI	P value
Sex							
Male	25(50.0)	Ref					
Female	25(50.0)	0.724	0.269-1.950	0.523			
Age							
≤60 years old	36(72.0)	Ref			Ref		
>60 years old	14(28.0)	2.83	1.014-7.897	0.047	1.427	0.441-4.617	0.553
Smoking history							
Smoking	15(30.0)	Ref					
Never	35(70.0)	1.017	0.352-2.935	0.976			
Family history of cancer							
Yes	6(12.0)	Ref					
No	44(88.0)	1.104	0.249-4.885	0.897			
Initial symptom							
Yes	43(86.0)	Ref					
No	7(17.0)	0.992	0.225-4.377	0.991			
ECOG PS							
0	10(20.0)	Ref					
1-2	40(80.0)	1.581	0.359-6.961	0.544			
IPI							
0-1	9(18.0)	Ref					
2-5	41(82.0)	4.205	0.552-32.059	0.166			
LDH							
Normal	30(60.0)	Ref			Ref		
Elevated	20(40.0)	3.257	1.175-9.026	0.023	2.294	0.746-7.054	0.148
β2-MG							
Normal	33(66.0)				Ref		
Elevated	17(34.0)	3.357	1.242-9.074	0.017	2.328	0.766-7.076	0.136
Extent of tumor invasion							
Single lobe	6(12.0)	Ref					
≥2 lobes	44(88.0)	26.089	0.054-12587.107	0.301			
Location							
Left lung	26(52.0)	Ref					
Right lung	21(42.0)	1.086	0.402-2.938	0.871			
Bilateral lungs	3(6.0)	0	0.000-0.000	0.983			
Clinical stage							
IE-II1E	13(26.0)	Ref					
II2E-IV	37(74.0)	6.176	0.814-46.830	0.078			
Therapeutic method							
Surgery	13(26.0)	Ref					
Non-surgery	37(74.0)	7.539	0.982-57.851	0.052			

OS, overall survival; MALT, mucosa-associated lymphoid tissue; HR, hazard ratio; CI, confidence interval; Ref, reference; ECOG PS, eastern cooperative oncology group performance status; IPI, international prognostic index; LDH, lactate dehydrogenase; β2-MG, β2-microglobulin.

Table S2 Univariate and multivariate analyses of OS in 40 cases of MALT lymphoma

Factors	No. (%)	Univariate analysis			Multivariate analysis		
		HR	95% CI	P-value	HR	95% CI	P value
Sex							
Male	18(45.0)	Ref					
Female	22(55.0)	0.484	0.167-1.404	0.182			
Age							
≤60 years old	24(60.0)	Ref					
>60 years old	16(40.0)	2.597	0.891-7.572	0.081			
Smoking history							
Smoking	10(25.0)	Ref					
Never	30(75.0)	0.898	0.240-3.358	0.873			
Family history of cancer							
Yes	8(20.0)	Ref					
No	32(80.0)	0.622	0.166-2.324	0.480			
Initial symptom							
Yes	25(62.5)	Ref					
No	15(37.5)	0.412	0.108-1.564	0.192			
ECOG PS							
0	14(35.0)	Ref					
1-2	26(65.0)	2.176	0.567-8.350	0.257			
IPI							
0-1	21(52.5)	Ref					
2-5	19(47.5)	1.896	0.632-5.689	0.254			
LDH							
Normal	35(87.5)	Ref					
Elevated	5(12.5)	1.060	0.237-4.753	0.939			
β2-MG							
Normal	22(55.0)	Ref					
Elevated	18(45.0)	1.198	0.419-3.425	0.735			
Extent of tumor invasion							
Single lobe	8(20.0)	Ref					
≥2 lobes	32(80.0)	0.845	0.235-3.037	0.797			
Location							
Left lung	13(32.5)	Ref					
Right lung	23(57.5)	0.998	0.326-3.057	0.997			
Bilateral lungs	4(10.0)	0.830	0.096-7.169	0.866			
Clinical stage							
IE-II1E	21(52.5)	Ref					
II2E-IV	19(47.5)	2.365	0.738-7.582	0.147			
Therapeutic method							
Surgery	27(67.5)	Ref					
Non-surgery	13(32.5)	1.242	0.413-3.732	0.700			

OS, overall survival; MALT, mucosa-associated lymphoid tissue; HR, hazard ratio; CI, confidence interval; Ref, reference; ECOG PS, eastern cooperative oncology group performance status; IPI, international prognostic index; LDH, lactate dehydrogenase; β2-MG, β2-microglobulin.